---
created: 2025-04-13
updated: 2025-04-13T10:52
id: mpd>RD_Y{c
specialty: cardio
specialty_id: 152
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::07-cardiovascular::05-pharm::03-calcium-channel-blockers
  - "source/ak-step1-v11:": 
  - theme/nbme::29
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::09-cardiac
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::10-cardiac::01-hypertension-treatment
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::10-cardiac::02-calcium-channel-blockers
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::02-cardio-&-renal::03-antihypertensives::01-calcium-channel-blockers
  - "source/ak-step1-v11:": 
  - theme/uworld::1000-9999::6000-6999::6754
  - source/ak-step1-v11::^other::^highyield::1-highyield
  - source/ak-step1-v11::^systems::cardio::pharmacology
  - "source/ak-step2-v11:": 
  - theme/b&b::01-cardiology::pharm::cvs-pharm-1
type: flashcard
---

# Question
What antihypertensive effect do dihydropyridine CCBs (eg, amlodipine and nifedipine) have on afterload?    **Decreased afterload (via peripheral vasodilation)**

---

# Answer
potent arteriolar vasodilators = decrease BP by decreasing vascular peripheral resistance  via inhibition of calcium influx into vascular smooth mm cells == vasodilation & dec peripheral arteriolar resistance  In contrast with nondihydropyridine CCBs, these CCBs have minimal activity on cardiomyocytes